Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Piper Sandler bullish on Acelyrin stock, cites major catalysts on horizon

EditorEmilio Ghigini
Published 24/05/2024, 10:22 pm
© Reuters.
SLRN
-

On Friday, Piper Sandler affirmed its Overweight rating on Acelyrin Inc (NASDAQ:SLRN) stock, with a stable price target of $68.00. The firm's positive stance comes in anticipation of significant upcoming events for Acelyrin in the second half of 2024, which are expected to be major catalysts for the biotech company.

According to the investment firm, Acelyrin's stock is currently undervalued when considering its pipeline potential. The firm highlighted that the latter half of 2024 will be data-rich for Acelyrin, with several key developments on the horizon that investors should be aware of.

These include the anticipated results from the izokibep Hidradenitis Suppurativa (HS) study in the third quarter of 2024, which could further confirm the treatment's rapid onset, effectiveness, and safety profile.

In addition to the izokibep HS data, Acelyrin is expected to announce a second significant readout for a uveitis treatment by the end of 2024. This readout carries a high probability of success, according to Piper Sandler. Furthermore, the initiation of a Phase 2b/3 trial for lonigutamab in Thyroid Eye Disease (TED) is projected to take place in the second half of the year.

The firm underscored the importance of these upcoming datasets, stating that they are critical for Acelyrin's future decisions regarding the path to potential approval of their treatments. Piper Sandler's commentary reflects a sense of optimism about the company's prospects, as these data releases could play a pivotal role in shaping Acelyrin's trajectory in the near future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.